DocGo Inc. Selling and Marketing Expense
DocGo Inc. (DCGO) reported Selling and Marketing Expense of $423.29 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-17
- DocGo Inc. selling and marketing expense for the quarter ending 2026-06-30 was $423.29K, a 14.96% increase year-over-year.
- DocGo Inc. selling and marketing expense for the quarter ending 2026-03-31 was $372.63K, a 12.34% increase year-over-year.
- DocGo Inc. selling and marketing expense for the quarter ending 2025-12-31 was $340.34K, a 14.24% decline year-over-year.
- DocGo Inc. selling and marketing expense for the quarter ending 2025-09-30 was $380.17K, a 0.10% increase year-over-year.
- DocGo Inc. selling and marketing expense for fiscal 2025 was $1.42M, a 5.68% decline from fiscal 2024.
- DocGo Inc. selling and marketing expense for fiscal 2024 was $1.51M, a 46.25% decline from fiscal 2023.
- DocGo Inc. selling and marketing expense for fiscal 2023 was $2.80M, a 41.08% decline from fiscal 2022.
- DocGo Inc. selling and marketing expense for fiscal 2022 was $4.76M, a 0.06% decline from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $423.29K 10-Q · filed 2026-08-17 | $795.93K 10-Q · filed 2026-08-17 | $1.14M derived: sum of 3 quarters · filed 2026-08-17 | $1.52M derived: sum of 4 quarters · filed 2026-08-17 |
| 2026-03-31 | $372.63K 10-Q · filed 2026-05-11 | $712.97K derived: sum of 2 quarters · filed 2026-05-11 | $1.09M derived: sum of 3 quarters · filed 2026-05-11 | $1.46M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-12-31 | $340.34K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $720.51K derived: sum of 2 quarters · filed 2026-03-16 | $1.09M derived: sum of 3 quarters · filed 2026-08-17 | $1.42M 10-K · filed 2026-03-16 |
| 2025-09-30 | $380.17K 10-Q · filed 2025-11-10 | $748.39K derived: sum of 2 quarters · filed 2026-08-17 | $1.08M 10-Q · filed 2025-11-10 | $1.48M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-06-30 | $368.21K 10-Q · filed 2026-08-17 | $699.92K 10-Q · filed 2026-08-17 | $1.10M derived: sum of 3 quarters · filed 2026-08-17 | $1.48M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-03-31 | $331.70K 10-Q · filed 2026-05-11 | $728.53K derived: sum of 2 quarters · filed 2026-05-11 | $1.11M derived: sum of 3 quarters · filed 2026-05-11 | $1.50M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $396.83K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $776.61K derived: sum of 2 quarters · filed 2026-03-16 | $1.17M derived: sum of 3 quarters · filed 2026-03-16 | $1.51M 10-K · filed 2026-03-16 |
| 2024-09-30 | $379.78K 10-Q · filed 2025-11-10 | $772.06K derived: sum of 2 quarters · filed 2025-11-10 | $1.11M 10-Q · filed 2025-11-10 | $1.31M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-06-30 | $392.28K 10-Q · filed 2025-08-07 | $729.29K 10-Q · filed 2025-08-07 | $932.84K derived: sum of 3 quarters · filed 2026-03-16 | $2.54M derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-03-31 | $337.01K 10-Q · filed 2025-05-08 | $540.56K derived: sum of 2 quarters · filed 2026-03-16 | $2.15M derived: sum of 3 quarters · filed 2026-03-16 | $2.83M derived: sum of 4 quarters · filed 2026-03-16 |
| 2023-12-31 | $203.55K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.81M derived: sum of 2 quarters · filed 2026-03-16 | $2.49M derived: sum of 3 quarters · filed 2026-03-16 | $2.80M 10-K · filed 2026-03-16 |
| 2023-09-30 | $1.61M 10-Q · filed 2024-11-07 | $2.29M derived: sum of 2 quarters · filed 2024-11-07 | $2.60M 10-Q · filed 2024-11-07 | $5.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $685.39K 10-Q · filed 2024-08-07 | $992.63K 10-Q · filed 2024-08-07 | $3.40M derived: sum of 3 quarters · filed 2025-02-27 | $3.49M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $307.25K 10-Q · filed 2024-05-08 | $2.71M derived: sum of 2 quarters · filed 2025-02-27 | $2.80M derived: sum of 3 quarters · filed 2025-02-27 | $3.80M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.50M derived: sum of 2 quarters · filed 2025-02-27 | $3.50M derived: sum of 3 quarters · filed 2025-02-27 | $4.76M 10-K · filed 2025-02-27 |
| 2022-09-30 | $90.86K 10-Q · filed 2023-11-06 | $1.09M derived: sum of 2 quarters · filed 2023-11-06 | $2.35M 10-Q · filed 2023-11-06 | $4.08M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $1.00M 10-Q · filed 2023-08-08 | $2.26M 10-Q · filed 2023-08-08 | $3.99M derived: sum of 3 quarters · filed 2024-02-28 | $4.98M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.26M 10-Q · filed 2023-05-09 | $2.99M derived: sum of 2 quarters · filed 2024-02-28 | $3.98M derived: sum of 3 quarters · filed 2024-02-28 | $5.17M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.72M derived: sum of 2 quarters · filed 2024-02-28 | $3.91M derived: sum of 3 quarters · filed 2024-02-28 | $4.76M 10-K · filed 2024-02-28 |
| 2021-09-30 | $994.40K 10-Q · filed 2022-11-08 | $2.18M derived: sum of 2 quarters · filed 2022-11-08 | $3.03M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $1.19M 10-Q · filed 2022-08-09 | $2.03M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $842.86K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $746.24K 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B | ||
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |